Impact of TPS calculation algorithms on dose delivered to the patient in proton therapy treatments

To estimate the impact of dose calculation approaches adopted in different treatment planning systems (TPSs) on proton therapy dose delivered with pencil beam scanning (PBS). Treatment plans for six regular volumes in water and 15 clinical cases were optimized with Syngo-VC13 and exported for forwar...

Full description

Saved in:
Bibliographic Details
Main Authors: Molinelli, Silvia (Author) , Mairani, Andrea (Author)
Format: Article (Journal)
Language:English
Published: 4 April 2019
In: Physics in medicine and biology
Year: 2019, Volume: 64, Issue: 7
ISSN:1361-6560
DOI:10.1088/1361-6560/ab0a4d
Online Access:Verlag, Volltext: https://doi.org/10.1088/1361-6560/ab0a4d
Verlag: https://doi.org/10.1088%2F1361-6560%2Fab0a4d
Get full text
Author Notes:Silvia Molinelli, Stefania Russo, Giuseppe Magro, Davide Maestri, Andrea Mairani, Edoardo Mastella, Alfredo Mirandola, Alessandro Vai, Barbara Vischioni, Francesca Valvo and Mario Ciocca
Description
Summary:To estimate the impact of dose calculation approaches adopted in different treatment planning systems (TPSs) on proton therapy dose delivered with pencil beam scanning (PBS). Treatment plans for six regular volumes in water and 15 clinical cases were optimized with Syngo-VC13 and exported for forward recalculation with Raystation-V7.0 pencil beam (RS-PBA) and Monte Carlo (RS-MC) algorithms and with the independent Fluka-MC engine. To verify clinical consistency between the two TPS dosimetric outcomes, the average percentage variations of clinical target volume (CTV) D 98%, D 50% and D 2%, adopted for plan prescription and evaluation, were considered. Ionization chamber measurements served as a further reference for comparison in homogeneous conditions. CTV dose volume histogram (DVH) analysis and gamma evaluation with 3 mm—3% agreement criteria quantified the dose deviation of TPS calculation algorithms, in heterogeneous conditions, against the Fluka-MC code. CTV D 50%, representing the plan dose prescription goal, was higher on average over H&N cases of (3.9 ± 0.9)% and (2.3 ± 0.6)% as calculated with RS-PBA and RS-MC, respectively, compared to Syngo. For tumors located in the pelvis district, average D 50% variations of (1.6 ± 0.7)% and (1.2 ± 0.7)% were found. Syngo underestimated target near maximum doses with respect to all computation systems. Calculation accuracy in heterogeneous conditions of RS-PBA H&N plans resulted poor when a range shifter was required. Target DVH and γ-analysis showed excellent agreement between RS-MC and Fluka-MC, with γ-pass rates >98% for all patient groups. Different TPS dose calculation approaches mainly affected dose delivered in H&N proton treatments, while minor deviations were found for pelvic tumors. RS-MC proved to be the most accurate TPS dose calculation algorithm when compared to an independent MC simulation code.
Item Description:Gesehen am 29.01.2020
Physical Description:Online Resource
ISSN:1361-6560
DOI:10.1088/1361-6560/ab0a4d